# RECURSION PHARMACEUTICALS, INC. (RXRX) FY2026 Q2 P&L / Income Statement

- Company: RECURSION PHARMACEUTICALS, INC. (RXRX)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001601830-26-000098
- Page: https://plicit.ai/financials/rxrx/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/rxrx-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenue**: 7,670,000 US dollars
- **Cost of revenue**: 11,491,000 US dollars
- **Gross profit (calculated)**: negative 3,821,000 US dollars
- **Operating expenses (calculated)**: 131,147,000 US dollars
- **Loss from operations**: negative 134,968,000 US dollars
- **Other income (loss), net**: 3,962,000 US dollars
- **Loss before income tax benefit**: negative 131,006,000 US dollars
- **Income tax benefit**: negative 1,000 US dollars
- **Net loss**: negative 131,005,000 US dollars
- **Operating revenue**: 7,303,000 US dollars
- **Grant revenue**: 367,000 US dollars
- **Research and development**: 89,614,000 US dollars
- **General and administrative**: 41,533,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.